Tolvaptan
Ended Awarded
- Contract number
- 36C25220N0295
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 12
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $10,035
Award facts
- Contract value 100% obligated
- $10,034.63 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
About this award
Otsuka America Pharmaceutical Inc. received a Blanket Purchase Agreement (BPA) call award from Veterans Integrated Service Network 12 for tolvaptan, a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract, valued at $10,034.63 on a firm fixed price basis, was awarded on April 1, 2020, with an ultimate completion date of April 10, 2020. The place of performance is Pittsburgh, Pennsylvania. This award was issued without a set-aside designation, reflecting the vendor's status as an established large pharmaceutical manufacturer. The contract falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), which enables streamlined procurement of critical medications.
This BPA call is part of Otsuka America Pharmaceutical Inc.'s larger Indefinite Delivery Vehicle with the VA, which includes an $83.3 million blanket purchase agreement for Jynarque (tolvaptan) through the National Acquisition Center. The company maintains an additional $396 million Federal Supply Schedule contract for pharmaceuticals and hematology products, demonstrating its significant capability and established relationship with the Department of Veterans Affairs. These delivery orders support the VA's mission of providing specialized pharmaceutical treatments to veterans across multiple Integrated Service Networks nationwide.
Quick answers
Who was awarded contract 36C25220N0295?
36C25220N0295 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 12 (Veterans Health Administration) on April 1, 2020.
How much is contract 36C25220N0295 worth?
The government has obligated $10,035 on 36C25220N0295.
Is contract 36C25220N0295 an order under another contract?
Yes. 36C25220N0295 is a BPA call under 36F79720D0099-36E79720A0007, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25220N0295 competed?
The extent of competition for 36C25220N0295 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award